HRX-0233

Revisión del cliente

Based on 1 Customer Validation

HRX-0233 is an orally potent MAP2K4 inhibitor. HRX-0233 inhibits the MAP2K4-JNK-JUN signaling pathway, blocks the feedback activation of receptor tyrosine kinases, and sustains the inhibitory effect on KRAS signaling. HRX-0233 exerts synergistic inhibition on the mTORC1 and MAPK pathways. When combined with Ipatasertib (HY-15186) or Sotorasib (HY-114277), it produces synergistic antiproliferative, pro-apoptotic (apoptosis) and antitumor effects, and shows good tolerability in mouse models. HRX-0233 can be used in CRISPR knockout screens to identify vulnerability-related genes. HRX-0233 is applicable to research related to prostate cancer, non-small cell lung cancer and colorectal cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 98.92%
  • No. CAS: 2409140-12-9
  • Fòrmula: C24H21F2N5O3S
  • Peso molecular:497.52
  • Almacenamiento:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Protocolo
  • Pureza y Documentación
  • Referencias
  • Help & FAQs

Ver todos los productos específicos de isoformas MEK

More

Ver todos los productos específicos de isoformas mTOR

More
MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00